Hepatitis C virus: Why do we need a vaccine to prevent a curable persistent infection?

Current Opinion in Immunology

Volumn 35, Issue , 2015, Pages 137-143

  Walker, Christopher M ^a   Grakoui, Arash ^b,c  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C VACCINE; HEPATITIS VACCINE; NEUTRALIZING ANTIBODY; VIRAL PROTEIN; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG EFFICACY; FEASIBILITY STUDY; HEPATITIS C; HUMAN; HUMAN NEEDS; IMMUNE RESPONSE; INFECTION PREVENTION; NONHUMAN; PERSISTENT INFECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; VACCINATION; VACCINE PRODUCTION; VIRUS NEUTRALIZATION; ANIMAL; CLINICAL TRIAL (TOPIC); HEPACIVIRUS; HEPATITIS C, CHRONIC; IMMUNOLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CLINICAL TRIALS AS TOPIC; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; VIRAL ENVELOPE PROTEINS; VIRAL HEPATITIS VACCINES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84938603864     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2015.06.010     Document Type: Review

References (50)

1. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244:359-362.
2. Mohd Hanafiah K., Groeger J., Flaxman A.D., Wiersma S.T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013, 57:1333-1342.
3. Lauer G.M., Walker B.D. Hepatitis C virus infection. N Engl J Med 2001, 345:41-52.
4. Suryaprasad A.G., White J.Z., Xu F., Eichler B.A., Hamilton J., Patel A., Hamdounia S.B., Church D.R., Barton K., Fisher C., et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis 2014, 59:1411-1419.
5. Hepatitis C virus infection among adolescents and young adults: Massachusetts, 2002-2009. Morb Mortal Wkly Rep 2011, 60:537-541.
6. Hagan L.M., Wolpe P.R., Schinazi R.F. Treatment as prevention and cure towards global eradication of hepatitis C virus. Trends Microbiol 2013, 21:625-633.
7. Dahari H., Feinstone S.M., Major M.E. Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology 2010, 139:965-974.
8. Grebely J., Prins M., Hellard M., Cox A.L., Osburn W.O., Lauer G., Page K., Lloyd A.R., Dore G.J. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 2012, 12:408-414.
9. Osburn W.O., Fisher B.E., Dowd K.A., Urban G., Liu L., Ray S.C., Thomas D.L., Cox A.L. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2009, 138:315-324.
10. Smith D.B., Bukh J., Kuiken C., Muerhoff A.S., Rice C.M., Stapleton J.T., Simmonds P. Expanded classification of hepatitis C Virus into 7 genotypes and 67 subtypes: updated criteria and assignment web resource. Hepatology 2014, 59:318-327.
11. Liang T.J. Current progress in development of hepatitis C virus vaccines. Nat Med 2013, 19:869-878.
12. Akazawa D., Moriyama M., Yokokawa H., Omi N., Watanabe N., Date T., Morikawa K., Aizaki H., Ishii K., Kato T., et al. Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice. Gastroenterology 2013, 145:447-455. e441-444.
13. Houghton M. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev 2011, 239:99-108.
14. Folgori A., Capone S., Ruggeri L., Meola A., Sporeno E., Ercole B.B., Pezzanera M., Tafi R., Arcuri M., Fattori E., et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006, 12:190-197.
15. Ball J.K., Tarr A.W., McKeating J.A. The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res 2014, 105:100-111.
16. Billerbeck E., de Jong Y., Dorner M., de la Fuente C., Ploss A. Animal models for hepatitis C. Curr Top Microbiol Immunol 2013, 369:49-86.
17. Dorner M., Horwitz J.A., Donovan B.M., Labitt R.N., Budell W.C., Friling T., Vogt A., Catanese M.T., Satoh T., Kawai T., et al. Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature 2013, 501:237-241.
18. Khan A.G., Whidby J., Miller M.T., Scarborough H., Zatorski A.V., Cygan A., Price A.A., Yost S.A., Bohannon C.D., Jacob J., et al. Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature 2014, 509:381-384.
19. Kong L., Giang E., Nieusma T., Kadam R.U., Cogburn K.E., Hua Y., Dai X., Stanfield R.L., Burton D.R., Ward A.B., et al. Hepatitis C virus E2 envelope glycoprotein core structure. Science 2013, 342:1090-1094.
20. Farci P., Shimoda A., Wong D., Cabezon T., De Gioannis D., Strazzera A., Shimizu Y., Shapiro M., Alter H.J., Purcell R.H. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A 1996, 93:15394-15399.
21. Morin T.J., Broering T.J., Leav B.A., Blair B.M., Rowley K.J., Boucher E.N., Wang Y., Cheslock P.S., Knauber M., Olsen D.B., et al. Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog 2012, 8:e1002895.
22. Law M., Maruyama T., Lewis J., Giang E., Tarr A.W., Stamataki Z., Gastaminza P., Chisari F.V., Jones I.M., Fox R.I., et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2008, 14:25-27.
23. Vanwolleghem T., Bukh J., Meuleman P., Desombere I., Meunier J.C., Alter H., Purcell R.H., Leroux-Roels G. Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology 2008, 47:1846-1855.
24. Krawczynski K., Alter M.J., Tankersley D.L., Beach M., Robertson B.H., Lambert S., Kuo G., Spelbring J.E., Meeks E., Sinha S., et al. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 1996, 173:822-828.
25. de Jong Y.P., Dorner M., Mommersteeg M.C., Xiao J.W., Balazs A.B., Robbins J.B., Winer B.Y., Gerges S., Vega K., Labitt R.N., et al. Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Sci Transl Med 2014, 6:254ra129.
26. Dowd K.A., Netski D.M., Wang X.H., Cox A.L., Ray S.C. Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology 2009, 136:2377-2386.
27. von Hahn T., Yoon J.C., Alter H., Rice C.M., Rehermann B., Balfe P., McKeating J.A. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007, 132:667-678.
28. Osburn W.O., Snider A.E., Wells B.L., Latanich R., Bailey J.R., Thomas D.L., Cox A.L., Ray S.C. Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology 2014, 59:2140-2151.
29. Lavillette D., Morice Y., Germanidis G., Donot P., Soulier A., Pagkalos E., Sakellariou G., Intrator L., Bartosch B., Pawlotsky J.M., et al. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 2005, 79:6023-6034.
30. Pestka J.M., Zeisel M.B., Blaser E., Schurmann P., Bartosch B., Cosset F.L., Patel A.H., Meisel H., Baumert J., Viazov S., et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A 2007, 104:6025-6030.
31. Osburn W.O., Fisher B.E., Dowd K.A., Urban G., Liu L., Ray S.C., Thomas D.L., Cox A.L. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010, 138:315-324.
32. Brimacombe C.L., Grove J., Meredith L.W., Hu K., Syder A.J., Flores M.V., Timpe J.M., Krieger S.E., Baumert T.F., Tellinghuisen T.L., et al. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol 2011, 85:596-605.
33. Timpe J.M., Stamataki Z., Jennings A., Hu K., Farquhar M.J., Harris H.J., Schwarz A., Desombere I., Roels G.L., Balfe P., et al. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 2008, 47:17-24.
34. Witteveldt J., Evans M.J., Bitzegeio J., Koutsoudakis G., Owsianka A.M., Angus A.G., Keck Z.Y., Foung S.K., Pietschmann T., Rice C.M., et al. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol 2009, 90:48-58.
35. Meunier J.C., Gottwein J.M., Houghton M., Russell R.S., Emerson S.U., Bukh J., Purcell R.H. Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J Infect Dis 2011, 204:1186-1190.
36. Law J.L., Chen C., Wong J., Hockman D., Santer D.M., Frey S.E., Belshe R.B., Wakita T., Bukh J., Jones C.T., et al. A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS One 2013, 8:e59776.
37. Frey S.E., Houghton M., Coates S., Abrignani S., Chien D., Rosa D., Pileri P., Ray R., Di Bisceglie A., Rinella P., et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 2010.
38. Abdel-Hakeem M.S., Shoukry N.H. Protective immunity against hepatitis C: many shades of gray. Front Immunol 2014, 5:274.
39. Lauer G.M. Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies. J Infect Dis 2013, 207(Suppl. 1):S7-S12.
40. Major M.E., Mihalik K., Puig M., Rehermann B., Nascimbeni M., Rice C.M., Feinstone S.M. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol 2002, 76:6586-6595.
41. Shoukry N.H., Grakoui A., Houghton M., Chien D.Y., Ghrayeb J., Reimann K.A., Walker C.M. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003, 197:1645-1655.
42. Grakoui A., Shoukry N.H., Woollard D.J., Han J.H., Hanson H.L., Ghrayeb J., Murthy K.K., Rice C.M., Walker C.M. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003, 302:659-662.
43. Park S.H., Shin E.C., Capone S., Caggiari L., De Re V., Nicosia A., Folgori A., Rehermann B. Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus. Gastroenterology 2012, 143:1048-1060. e1044.
44. Barnes E., Folgori A., Capone S., Swadling L., Aston S., Kurioka A., Meyer J., Huddart R., Smith K., Townsend R., et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012, 4:115ra111.
45. Swadling L., Capone S., Antrobus R.D., Brown A., Richardson R., Newell E.W., Halliday J., Kelly C., Bowen D., Fergusson J., et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med 2014, 6:261ra153.
46. Puig M., Mihalik K., Tilton J.C., Williams O., Merchlinsky M., Connors M., Feinstone S.M., Major M.E. CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus. Hepatology 2006, 44:736-745.
47. Chmielewska A.M., Naddeo M., Capone S., Ammendola V., Hu K., Meredith L., Verhoye L., Rychlowska M., Rappuoli R., Ulmer J.B., et al. Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses. J Virol 2014, 88:5502-5510.
48. Martin B., Hennecke N., Lohmann V., Kayser A., Neumann-Haefelin C., Kukolj G., Bocher W.O., Thimme R. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. J Hepatol 2014, 61:538-543.
49. Callendret B., Eccleston H.B., Hall S., Satterfield W., Capone S., Folgori A., Cortese R., Nicosia A., Walker C.M. T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee. Hepatology 2014, 60:1531-1540.
50. Park S.H., Veerapu N.S., Shin E.C., Biancotto A., McCoy J.P., Capone S., Folgori A., Rehermann B. Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection. Nat Med 2013, 19:1638-1642.